Shots:
- The US FDA has granted BTD to lacutamab for the treatment of adults with r/r sézary syndrome after receiving ≥2L of therapy incl. mogamulizumab
- Designation was based on P-I as well as P-II (TELLOMAK) trial data, showing efficacy & favorable safety in pts who were heavily pre-treated with mogamulizumab
- Additionally, Lacutamab (anti-KIR3DL2 mAb) is expected to enter P-III trial for CTCL, with Innate actively seeking a partner
Ref: Businesswire | Image: Innate Pharma
Related News:- Innate Pharma Reports Results from the P-II Study (TELLOMAK) of Lacutamab for Sézary Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
